Filter By Industry
Filter By Tag

Press Room

NAPSRx Press releases

1 - 10 of 345 Press Releases

May 28, 2015
Valeant Pharmaceutical’s wholly owned subsidiary, Salix Pharmaceuticals, Inc received approval from the U.S. Food and Drug Administration (FDA) for Xifaxan® 550 mg to treat IBS-D (Irritable Bowel Syndrome with Diarrhea) in adults.

May 21, 2015
Johnson & Johnson (Janssen) plans to file regulatory approvals for 10 new products between 2014 and 2019, each with the potential to accumulate $1 billion in revenue plus 40 line extensions of existing and new medicines.

May 19, 2015
In a robust deal worth $8.05 billion, Endo Pharmaceuticals will acquire privately-held Par Pharmaceutical Holdings from TPG.

May 13, 2015
Baxter is ready to expand its oncology segment by acquiring Oncaspar® (pegaspargase) product portfolio from Sigma-Tau Finanziaria S.p.A for USD $900 million.

May 08, 2015
The investigational drug venetoclax has been granted Breakthrough Therapy Designation from the U.S.

May 06, 2015
Teva Pharmaceuticals has acquired Auspex Pharmaceuticals, Inc for all of the outstanding shares of common stock of Auspex at $101.00 per share in cash, totaling approximately $3.2 billion in enterprise value and approximately $3.5 billion in equity...

May 05, 2015
Isis Pharmaceuticals has entered into an agreement with Bayer Healthcare to commercialize and develop ISIS-FXIRx for the prevention of thrombosis.

Apr 30, 2015
On April 29, 2015, the U.S Food and Drug Administration (FDA) approved KYBELLA (deoxycholic acid) Injection manufactured by Kythera Biopharmaceuticals to improve Submental Fullness, or “Double Chin”.

Apr 27, 2015
Eli Lilly’s breakthrough cancer treatment CYRAMZA® (ramucirumab) has received another approval from the U.S Food and Drug Administration (FDA) making this the fourth approved indication for the treatment.

Apr 24, 2015
The U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted priority review for Abbvie’s all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with...



RSS Feed for NAPSRx Press Releases